Marta Castroviejo-Bermejo

Marta Castroviejo-Bermejo

Auto-generated profile, based on publicly available information

Marta Castroviejo-Bermejo

Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
VSVioleta Serra
Violeta Serra
AWAnderson T. Wang
Anderson T. Wang
MCMarta Castroviejo-Bermejo
Marta Castroviejo-Bermejo
UPUrszula M. Polanska
Urszula M. Polanska
MPMarta Palafox
Marta Palafox
MOMark J. O'COnnor
Mark J. O'COnnor
Purpose: PARP inhibitors (PARPi) induce synthetic lethality in homologous recombination repair (HRR)-deficient tumors and are used to treat breast, ovarian, pancreatic, and prostate cancers. Multiple PARPi resistance mechanisms exist, most resulting in restoration of HRR and protection of stalled replication forks. ATR inhibition was highlighted as a unique approach to reverse both aspects of resistance. Recently, however, a PARPi/WEE1 inhibitor (WEE1i) combination demonstrated enhanced antitumor activity associated with the induction of replication stress, suggesting another approach to tackling PARPi resistance. Experimental Design: We analyzed breast and ovarian patient-derived xenoimplant models resistant to PARPi to quantify WEE1i and ATR inhibitor (ATRi) responses as single agents and in combination with PARPi. Biomarker analysis was conducted at the genetic and protein level. Metabolite analysis by mass spectrometry and nucleoside rescue experiments ex vivo were also conducted in patient-derived models. Results: Although WEE1i response was linked to markers of replication stress, including STK11/RB1 and phospho-RPA, ATRi response associated with ATM mutation. When combined with olaparib, WEE1i could be differentiated from the ATRi/olaparib combination, providing distinct therapeutic strategies to overcome PARPi resistance by targeting the replication stress response. Mechanistically, WEE1i sensitivity was associated with shortage of the dNTP pool and a concomitant increase in replication stress. Conclusions: Targeting the replication stress response is a valid therapeutic option to overcome PARPi resistance including tumors without an underlying HRR deficiency. These preclinical insights are now being tested in several clinical trials where the PARPi is administered with either the WEE1i or the ATRi.

1 April 2023
Verified
Other
Open access
VSVioleta Serra
Violeta Serra
AWAnderson T. Wang
Anderson T. Wang
MCMarta Castroviejo-Bermejo
Marta Castroviejo-Bermejo
UPUrszula M. Polanska
Urszula M. Polanska
MPMarta Palafox
Marta Palafox
MOMark J. O'Connor
Mark J. O'Connor
Supplementary Data from Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

1 April 2023
Verified
Other
Open access
VSVioleta Serra
Violeta Serra
AWAnderson T. Wang
Anderson T. Wang
MCMarta Castroviejo-Bermejo
Marta Castroviejo-Bermejo
UPUrszula M. Polanska
Urszula M. Polanska
MPMarta Palafox
Marta Palafox
MOMark J. O'COnnor
Mark J. O'COnnor
Supplementary Figure from Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

1 April 2023
Verified
Other
Open access
VSVioleta Serra
Violeta Serra
AWAnderson T. Wang
Anderson T. Wang
MCMarta Castroviejo-Bermejo
Marta Castroviejo-Bermejo
UPUrszula M. Polanska
Urszula M. Polanska
MPMarta Palafox
Marta Palafox
MOMark J. O'COnnor
Mark J. O'COnnor
Supplementary Figure from Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

1 April 2023
Verified
Other
Open access
VSVioleta Serra
Violeta Serra
AWAnderson T. Wang
Anderson T. Wang
MCMarta Castroviejo-Bermejo
Marta Castroviejo-Bermejo
UPUrszula M. Polanska
Urszula M. Polanska
MPMarta Palafox
Marta Palafox
MOMark J. O'Connor
Mark J. O'Connor
Purpose:PARP inhibitors (PARPi) induce synthetic lethality in homologous recombination repair (HRR)-deficient tumors and are used to treat breast, ovarian, pancreatic, and prostate cancers. Multiple PARPi resistance mechanisms exist, most resulting in restoration of HRR and protection of stalled replication forks. ATR inhibition was highlighted as a unique approach to reverse both aspects of resistance. Recently, however, a PARPi/WEE1 inhibitor (WEE1i) combination demonstrated enhanced antitumor activity associated with the induction of replication stress, suggesting another approach to tackling PARPi resistance.Experimental Design:We analyzed breast and ovarian patient-derived xenoimplant models resistant to PARPi to quantify WEE1i and ATR inhibitor (ATRi) responses as single agents and in combination with PARPi. Biomarker analysis was conducted at the genetic and protein level. Metabolite analysis by mass spectrometry and nucleoside rescue experiments ex vivo were also conducted in patient-derived models.Results:Although WEE1i response was linked to markers of replication stress, including STK11/RB1 and phospho-RPA, ATRi response associated with ATM mutation. When combined with olaparib, WEE1i could be differentiated from the ATRi/olaparib combination, providing distinct therapeutic strategies to overcome PARPi resistance by targeting the replication stress response. Mechanistically, WEE1i sensitivity was associated with shortage of the dNTP pool and a concomitant increase in replication stress.Conclusions:Targeting the replication stress response is a valid therapeutic option to overcome PARPi resistance including tumors without an underlying HRR deficiency. These preclinical insights are now being tested in several clinical trials where the PARPi is administered with either the WEE1i or the ATRi.

1 April 2023
Verified
Other
Open access
VSVioleta Serra
Violeta Serra
AWAnderson T. Wang
Anderson T. Wang
MCMarta Castroviejo-Bermejo
Marta Castroviejo-Bermejo
UPUrszula M. Polanska
Urszula M. Polanska
MPMarta Palafox
Marta Palafox
MOMark J. O'COnnor
Mark J. O'COnnor
Supplementary Data from Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance